ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $32.00 Average PT from Analysts

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $34.20.

ABVX has been the topic of a number of recent research reports. Piper Sandler began coverage on ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued an “overweight” rating and a $42.00 target price on the stock. Morgan Stanley increased their price objective on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They issued a “buy” rating and a $50.00 target price for the company. Finally, BTIG Research began coverage on shares of ABIVAX Société Anonyme in a research note on Monday. They set a “buy” rating and a $43.00 price target on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in ABIVAX Société Anonyme during the first quarter valued at about $81,000. Capstone Investment Advisors LLC bought a new stake in ABIVAX Société Anonyme during the 4th quarter valued at approximately $618,000. Ghisallo Capital Management LLC acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at approximately $642,000. Kennedy Capital Management LLC increased its position in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. bought a new position in ABIVAX Société Anonyme in the 1st quarter worth approximately $5,411,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

ABIVAX Société Anonyme Stock Performance

ABIVAX Société Anonyme stock opened at $14.30 on Monday. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02. The company’s fifty day simple moving average is $14.67 and its 200-day simple moving average is $12.70.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.